Works matching DE "ORPHAN drug laws"
Results: 91
Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Orphan drugs policies: a suitable case for treatment.
- Published in:
- 2014
- By:
- Publication type:
- Editorial
Gaucher disease in Mexico. Epidemiologic overview.
- Published in:
- Acta Pediatrica de Mexico, 2011, v. 32, n. 5, p. 277
- By:
- Publication type:
- Article
Improving the Incentives of the FDA Voucher Program for Neglected Tropical Diseases.
- Published in:
- Brown Journal of World Affairs, 2015, v. 21, n. 2, p. 224
- By:
- Publication type:
- Article
Commentary: A Rare Opportunity.
- Published in:
- Biochemistry & Molecular Biology Education, 2008, v. 36, n. 4, p. 302, doi. 10.1002/bmb.20212
- By:
- Publication type:
- Article
Opportunities and Threats of the Legally Facilitated Performance-Based Managed Entry Agreements in Slovakia: The Early-Adoption Perspective.
- Published in:
- Healthcare (2227-9032), 2023, v. 11, n. 8, p. 1179, doi. 10.3390/healthcare11081179
- By:
- Publication type:
- Article
ARE WE ADOPTING THE ORPHANS, OR CREATING THEM? MEDICAL ETHICS AND LEGAL JURISPRUDENTIAL GUIDANCE FOR PROPOSED CHANGES TO THE ORPHAN DRUG ACT.
- Published in:
- Washington University Jurisprudence Review, 2017, v. 9, n. 2, p. 295
- By:
- Publication type:
- Article
Developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care?
- Published in:
- British Journal of Cancer, 2012, v. 106, n. 1, p. 14, doi. 10.1038/bjc.2011.544
- By:
- Publication type:
- Article
In the March 2024 Issue of the Quarterly.
- Published in:
- Milbank Quarterly, 2024, v. 102, n. 1, p. 5, doi. 10.1111/1468-0009.12697
- By:
- Publication type:
- Article
The Orphan Drug Act at 40: Legislative Triumph and the Challenges of Success.
- Published in:
- Milbank Quarterly, 2024, v. 102, n. 1, p. 83, doi. 10.1111/1468-0009.12680
- By:
- Publication type:
- Article
An Empirical Review of Major Legislation Affecting Drug Development: Past Experiences, Effects, and Unintended Consequences.
- Published in:
- Milbank Quarterly, 2011, v. 89, n. 3, p. 450, doi. 10.1111/j.1468-0009.2011.00636.x
- By:
- Publication type:
- Article
Investigating the landscape of US orphan product approvals.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Adopting Solutions to Orphan Drug Shortages.
- Published in:
- U.C. Davis Law Review, 2015, v. 48, n. 5, p. 2077
- By:
- Publication type:
- Article
THE 340B PROGRAM: A FEDERAL PROGRAM IN DESPERATE NEED OF REVISION AFTER TWO-AND-A-HALF DECADES OF UNCERTAINTY.
- Published in:
- Journal of Health Care Law & Policy, 2019, v. 22, n. 2, p. 25
- By:
- Publication type:
- Article
The implementation of health technology assessment principles in public decisions concerning orphan drugs.
- Published in:
- European Journal of Clinical Pharmacology, 2020, v. 76, n. 6, p. 755, doi. 10.1007/s00228-020-02855-7
- By:
- Publication type:
- Article
Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU.
- Published in:
- European Journal of Clinical Pharmacology, 2013, v. 69, n. 4, p. 1009, doi. 10.1007/s00228-012-1423-2
- By:
- Publication type:
- Article
Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering--A Cross-Sectional Analysis.
- Published in:
- Oncologist, 2016, v. 21, n. 4, p. 487, doi. 10.1634/theoncologist.2015-0397
- By:
- Publication type:
- Article
Corrigendum to "The impact of the rare disease and Orphan Drug Act in Taiwan" [J Food Drug Anal 29 (2021) 717-725].
- Published in:
- Journal of Food & Drug Analysis, 2022, v. 30, n. 2, p. 282, doi. 10.38212/2224-6614.3407
- By:
- Publication type:
- Article
The impact of the rare disease and Orphan Drug Act in Taiwan.
- Published in:
- Journal of Food & Drug Analysis, 2021, v. 29, n. 4, p. 717, doi. 10.38212/2224-6614.3383
- By:
- Publication type:
- Article
The Orphan Drug Act: An Appropriate Approval Pathway for Treatments of Rare Diseases?
- Published in:
- Hospital Pharmacy, 2019, v. 54, n. 5, p. 283, doi. 10.1177/0018578719867665
- By:
- Publication type:
- Article
TURNING ORPHANS FOR A PROFIT: THE ORPHAN DRUG ACT IS DUE FOR AN OVERHAUL.
- Published in:
- Hofstra Law Review, 2021, v. 49, n. 2, p. 569
- By:
- Publication type:
- Article
Anticipating Reforms to the Prescription Drug User Fees Act.
- Published in:
- 2022
- By:
- Publication type:
- Opinion
Negotiating prices of drugs for rare diseases.
- Published in:
- 2016
- By:
- Publication type:
- Opinion
Rare Disease Funding: A Rawlsian Approach to Orphan Drug Legislation.
- Published in:
- Penn Bioethics Journal, 2015, v. 11, n. 2, p. 13
- By:
- Publication type:
- Article
Addressing the authorization of orphan drugs will not fix reimbursement problems: The elephant is still in the room.
- Published in:
- Canadian Pharmacists Journal, 2013, v. 146, n. 5, p. 245, doi. 10.1177/1715163513499127
- By:
- Publication type:
- Article
Regulatory Framework for Drug Development in Rare Diseases.
- Published in:
- Journal of Clinical Pharmacology, 2022, v. 62, p. S15, doi. 10.1002/jcph.2171
- By:
- Publication type:
- Article
Legislation, regulation and policies issues of orphan drugs in developed countries from 2010 to 2016.
- Published in:
- Journal of Applied Biomedicine, 2018, v. 16, n. 3, p. 175, doi. 10.1016/j.jab.2018.04.002
- By:
- Publication type:
- Article
A COMPARISON OF THE PRE-MARKET ORPHAN DRUG LEGAL FRAMEWORKS IN THE UNITED STATES AND THE EUROPEAN UNION.
- Published in:
- Wisconsin International Law Journal, 2017, v. 35, n. 1, p. 138
- By:
- Publication type:
- Article
Capture and passive predation in times of COVID-19 pandemic.
- Published in:
- Public Choice, 2022, v. 193, n. 3/4, p. 163, doi. 10.1007/s11127-022-01005-0
- By:
- Publication type:
- Article
History of Orphan Drug Regulation-United States and Beyond.
- Published in:
- Clinical Pharmacology & Therapeutics, 2016, v. 100, n. 4, p. 342, doi. 10.1002/cpt.426
- By:
- Publication type:
- Article
The Future of Orphan Drug Development.
- Published in:
- Clinical Pharmacology & Therapeutics, 2012, v. 92, n. 2, p. 146, doi. 10.1038/clpt.2012.89
- By:
- Publication type:
- Article
The Challenges of Orphan Drugs and Orphan Diseases: Real and Imagined.
- Published in:
- Clinical Pharmacology & Therapeutics, 2012, v. 92, n. 2, p. 151, doi. 10.1038/clpt.2012.72
- By:
- Publication type:
- Article
The Impact of the Orphan Drug Act on the Development and Advancement of Neurological Products for Rare Diseases: A Descriptive Review.
- Published in:
- Clinical Pharmacology & Therapeutics, 2010, v. 88, n. 4, p. 449, doi. 10.1038/clpt.2010.193
- By:
- Publication type:
- Article
Orphan Drug Designation and Exclusivity for "Same Drugs".
- Published in:
- Journal of Law, Medicine & Ethics, 2019, v. 47, n. 2, p. 347, doi. 10.1177/1073110519857293
- Publication type:
- Article
Approximating Future Generic Entry for New Drugs.
- Published in:
- Journal of Law, Medicine & Ethics, 2019, v. 47, n. 1, p. 177, doi. 10.1177/1073110519840499
- By:
- Publication type:
- Article
Policymaking for Orphan Drugs and Its Challenges.
- Published in:
- AMA Journal of Ethics, 2015, v. 17, n. 8, p. 776, doi. 10.1001/journalofethics.2015.17.8.pfor2-1508
- By:
- Publication type:
- Article
INVESTIGATIONAL CONOPEPTIDE FOR CHRONIC INTRACTABLE PAIN GRANTED ORPHAN DRUG STATUS.
- Published in:
- Journal of Pain & Palliative Care Pharmacotherapy, 2006, v. 20, n. 1, p. 96
- Publication type:
- Article
Will crowdfunding and general solicitation spur orphan drug development for biotechs?
- Published in:
- Formulary, 2013, v. 48, n. 10, p. 343
- By:
- Publication type:
- Article
Orphan drug policies and use in pediatric nephrology.
- Published in:
- 2017
- By:
- Publication type:
- Editorial
Does an Orphan Drug Policy Make a Difference in Access? A Comparison of Canada and Australia.
- Published in:
- International Journal of Health Services, 2020, v. 50, n. 2, p. 166, doi. 10.1177/0020731419886526
- By:
- Publication type:
- Article
Incentivizing Therapies for Rare Diseases-Reply.
- Published in:
- 2019
- By:
- Publication type:
- Letter
Incentivizing Therapies for Rare Diseases.
- Published in:
- 2019
- By:
- Publication type:
- Letter
Incorrect Description of Drug Act.
- Published in:
- 2019
- Publication type:
- journal article
Do investors value the FDA orphan drug designation?
- Published in:
- 2017
- By:
- Publication type:
- journal article
Review of 11 national policies for rare diseases in the context of key patient needs.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Evolving prevalence of haematological malignancies in orphan designation procedures in the European Union.
- Published in:
- 2017
- By:
- Publication type:
- Letter
Challenges in orphan drug development and regulatory policy in China.
- Published in:
- 2017
- By:
- Publication type:
- journal article
The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Novel treatments for rare rheumatologic disorders: analysis of the impact of 30 years of the US orphan drug act.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Children's hospitals gain legislative victory on 340B orphan drugs.
- Published in:
- American Journal of Health-System Pharmacy, 2011, v. 68, n. 2, p. 100, doi. 10.2146/news110001
- By:
- Publication type:
- Article